Assessing the effectiveness of CAR-T cell therapies using advanced single-cell analysis.
Official title: High throughput CAR-T potency assay based on functional and transcriptional measurements on single cell co-cultures
Funded at Celldom, INC. · NIH-11077283 · Data updated 2026-11-12
This study is looking at ways to make CAR-T cell therapies better for people with aggressive cancers like leukemia and lymphoma by figuring out which types of CAR-T cells work best to fight the disease, so that treatments can be more personalized and effective for patients.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Celldom, INC. NIH-funded |
| Lab location | 1 site (San Carlos, UNITED STATES) |
| Project start | May 1, 2024 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $908,687 |
| NIH project number | 5R44CA281575-02 |
| Project ID | NIH-11077283 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with advanced leukemias or lymphomas who are considering or currently undergoing CAR-T cell therapy.
✕Less likely to help
Patients with cancers that are not responsive to CAR-T therapies or those who are not eligible for such treatments may not benefit from this research.
What this research studies
This research focuses on improving CAR-T cell therapies, which are innovative treatments for aggressive cancers like leukemias and lymphomas. By developing a high throughput assay that measures the potency of CAR-T cells at the single-cell level, the study aims to identify which specific cell populations are most effective in fighting cancer. This approach will help in understanding the diverse functions of CAR-T cells and their impact on patient outcomes, ultimately leading to more personalized and effective treatments.
Why it matters
Potential benefit: If successful, this research could enhance the effectiveness of CAR-T therapies, leading to better treatment outcomes for patients with aggressive cancers.
How similar studies have gone: Previous research has shown promising results in enhancing CAR-T cell therapies, but this specific approach using single-cell analysis is relatively novel.
Where this research is happening
-
Celldom, INC.
San Carlos, United States Active
Researchers
- Principal investigator: Yellen, Benjamin Biron — Celldom, INC.
- Study coordinator: Yellen, Benjamin Biron
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.